Company intelligence / Profile preview

Infinity BLC

Baltimore, Maryland, United Statesinfinitydrain.com ↗

Ownership: Private
Development stage: Other

Overview

Infinity Bio provides comprehensive antibody reactome profiling services using its proprietary MIPSA technology. This enables detailed mapping of immune responses for applications in infectious disease, autoimmunity, allergy, vaccine development, precision medicine, and biomarker discovery. The company recently launched MuSIGHT™, a mouse autoantibody reactome service for preclinical research. No direct clinical results as it does not develop therapeutics.

Therapeutic areas: ImmunologyOncologyInfectious Diseases
Modalities: Antibody
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Infinity BLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Infinity BLC.

Explore the full profile